BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12218956)

  • 1. Effect of hormone replacement therapy with femoston on hemostasis in peri- and postmenopausal women.
    Repina MA; Korzo TM; Zinina TA
    Med Sci Monit; 2002 Sep; 8(9):PI78-84. PubMed ID: 12218956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
    Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.
    Gelfand M; Fugère P; Bissonnette F
    Maturitas; 1997 Mar; 26(2):125-32. PubMed ID: 9089562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
    Quereux C; Pornel B; Bergeron C; Ferenczy A
    Maturitas; 2006 Feb; 53(3):299-305. PubMed ID: 16043317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women.
    Sator PG; Sator MO; Schmidt JB; Nahavandi H; Radakovic S; Huber JC; Hönigsmann H
    Climacteric; 2007 Aug; 10(4):320-34. PubMed ID: 17653959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
    van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
    Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution.
    Genazzani AR; Gambacciani M
    Gynecol Endocrinol; 2006 Mar; 22(3):145-50. PubMed ID: 16835076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension.
    Czarnecka D; Kawecka-Jaszcz K; Olszanecka A; Dembińska-Kieć A; Malczewska-Malec M; Zdzienicka A; Guevara I
    Med Sci Monit; 2004 Feb; 10(2):CR55-61. PubMed ID: 14737044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Hellgren M; Conard J; Norris L; Kluft C
    Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
    Kwok S; Charlton-Menys V; Pemberton P; McElduff P; Durrington PN
    Maturitas; 2006 Mar; 53(4):439-46. PubMed ID: 16139447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC; Rioux JE; Komer L; Gelfand M
    Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.